Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Hormone receptors and age distribution in breast cancer patients at a university hospital in northern egypt.

Hussein O, Mosbah M, Farouk O, Farag K, El-Saed A, Arafa M, Abdallah A.

Breast Cancer (Auckl). 2013 Jun 12;7:51-7. doi: 10.4137/BCBCR.S12214. Print 2013.

2.

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.

Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE.

J Natl Cancer Inst. 2012 Mar 7;104(5):406-14. doi: 10.1093/jnci/djr543. Epub 2012 Jan 16.

3.

Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?

Rack B, Janni W, Gerber B, Strobl B, Schindlbeck C, Klanner E, Rammel G, Sommer H, Dimpfl T, Friese K.

Breast Cancer Res Treat. 2003 Nov;82(2):83-92.

PMID:
14692652
4.

Impact of triple negative phenotype on breast cancer prognosis.

Kaplan HG, Malmgren JA.

Breast J. 2008 Sep-Oct;14(5):456-63. doi: 10.1111/j.1524-4741.2008.00622.x. Epub 2008 Jul 24.

PMID:
18657139
5.

Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer.

Cicin I, Karagol H, Usta U, Sezer A, Uzunoglu S, Alas-Cosar R, Yetisyigit T, Uygun K.

Med Oncol. 2009;26(3):335-43. doi: 10.1007/s12032-008-9126-3. Epub 2008 Nov 12.

PMID:
19003545
6.

The influence of young age on outcome in early stage breast cancer.

Fowble BL, Schultz DJ, Overmoyer B, Solin LJ, Fox K, Jardines L, Orel S, Glick JH.

Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33.

PMID:
8083119
7.

Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis.

Sanpaolo P, Barbieri V, Pedicini P, Fusco V.

Med Oncol. 2012 Jun;29(2):459-65. doi: 10.1007/s12032-011-9869-0. Epub 2011 Feb 26.

PMID:
21359639
8.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

9.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
10.

Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Oncol Rep. 2010 May;23(5):1213-20.

PMID:
20372832
11.

Clinicopathological features of triple-negative breast cancer in Taiwanese women.

Yao-Lung K, Dar-Ren C, Tsai-Wang C.

Int J Clin Oncol. 2011 Oct;16(5):500-5. doi: 10.1007/s10147-011-0211-9. Epub 2011 Apr 1.

PMID:
21455625
12.

Negative margin status improves local control in conservatively managed breast cancer patients.

Obedian E, Haffty BG.

Cancer J Sci Am. 2000 Jan-Feb;6(1):28-33.

PMID:
10696736
13.

Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.

Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI.

Cancer. 2005 Jun 1;103(11):2241-51.

14.

Study of HER2/neu status in Qatari women with breast carcinoma.

Rasul KI, Mohammaed K, Abdalla AS, Chong-Lopez A, Ahmad MA, Al-Homsi MU, Al-Hassan AM, Al-Alosi AS, Bener A.

Saudi Med J. 2003 Aug;24(8):832-6. Erratum in: Saudi Med J. 2003 Oct;24(10):1152. Bener, Bener A [corrected to Bener, Abdulbari].

PMID:
12939666
15.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

16.

Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.

Elledge RM, Clark GM, Chamness GC, Osborne CK.

J Natl Cancer Inst. 1994 May 4;86(9):705-12.

PMID:
7908990
17.

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.

18.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.

J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27.

19.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059. Epub 2012 Dec 13.

PMID:
23240985
20.

Blood type, hormone receptor status, HER2/neu status, and survival in breast cancer: a retrospective study exploring relationships in a phenotypically well-defined cohort.

Klimant E, Glurich I, Mukesh B, Onitilo AA.

Clin Med Res. 2011 Nov;9(3-4):111-8. doi: 10.3121/cmr.2011.907. Epub 2011 Jan 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk